A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
M.D. Anderson Cancer Center
Filamon LTD
Mayo Clinic
Washington University School of Medicine
University of Florida
Jonsson Comprehensive Cancer Center
University of Nebraska
Elephas
Novartis
Elephas
OncoNano Medicine, Inc.
Cancer Research UK
Massive Bio, Inc.
Washington University School of Medicine
University of Florida
Delfi Diagnostics Inc.
Medicenna Therapeutics, Inc.
DEKA Biosciences
Columbia University
Tempus AI
Turnstone Biologics, Corp.
Revolution Medicines, Inc.
Arbeitsgemeinschaft medikamentoese Tumortherapie
Stanford University
Cedars-Sinai Medical Center
Algemeen Ziekenhuis Maria Middelares
Checkpoint Therapeutics, Inc.
Taproot Health
VitaMed Research LLC
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
European Organisation for Research and Treatment of Cancer - EORTC
Sanguine Biosciences
National Cancer Institute (NCI)
UNICANCER
Klus Pharma Inc.
Revolution Medicines, Inc.
Bristol-Myers Squibb
Rush University Medical Center
Revolution Medicines, Inc.
Allarity Therapeutics
BioNTech SE
SpeciCare
Lumos Pharma
Celgene
M.D. Anderson Cancer Center
Stanford University
Stanford University
CureOne
Santa Maria Biotherapeutics